Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT)
(2022)
Journal Article
Maier, R. H., Plummer, C., Kasim, A. S., Akhter, N., Ogundimu, E., Maddox, J., …Austin, D. (2022). Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT). BMJ Open, 12(12), Article e066252. https://doi.org/10.1136/bmjopen-2022-066252
Introduction: Anthracyclines are included in chemotherapy regimens to treat several different types of cancer and are extremely effective. However, it is recognised that a significant side effect is cardiotoxicity; anthracyclines can cause irreversib... Read More about Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT).